TY - JOUR
T1 - Structure-based design of bacterial nitric oxide synthase inhibitors
AU - Holden, Jeffrey K.
AU - Kang, Soosung
AU - Hollingsworth, Scott A.
AU - Li, Huiying
AU - Lim, Nathan
AU - Chen, Steven
AU - Huang, He
AU - Xue, Fengtian
AU - Tang, Wei
AU - Silverman, Richard B.
AU - Poulos, Thomas L.
N1 - Publisher Copyright:
© 2014 American Chemical Society.
PY - 2015/1/22
Y1 - 2015/1/22
N2 - Inhibition of bacterial nitric oxide synthase (bNOS) has the potential to improve the efficacy of antimicrobials used to treat infections by Gram-positive pathogens Staphylococcus aureus and Bacillus anthracis. However, inhibitor specificity toward bNOS over the mammalian NOS (mNOS) isoforms remains a challenge because of the near identical NOS active sites. One key structural difference between the NOS isoforms is the amino acid composition of the pterin cofactor binding site that is adjacent to the NOS active site. Previously, we demonstrated that a NOS inhibitor targeting both the active and pterin sites was potent and functioned as an antimicrobial (Holden, Proc. Natl. Acad. Sci. U.S.A. 2013, 110, 18127). Here we present additional crystal structures, binding analyses, and bacterial killing studies of inhibitors that target both the active and pterin sites of a bNOS and function as antimicrobials. Together, these data provide a framework for continued development of bNOS inhibitors, as each molecule represents an excellent chemical scaffold for the design of isoform selective bNOS inhibitors.
AB - Inhibition of bacterial nitric oxide synthase (bNOS) has the potential to improve the efficacy of antimicrobials used to treat infections by Gram-positive pathogens Staphylococcus aureus and Bacillus anthracis. However, inhibitor specificity toward bNOS over the mammalian NOS (mNOS) isoforms remains a challenge because of the near identical NOS active sites. One key structural difference between the NOS isoforms is the amino acid composition of the pterin cofactor binding site that is adjacent to the NOS active site. Previously, we demonstrated that a NOS inhibitor targeting both the active and pterin sites was potent and functioned as an antimicrobial (Holden, Proc. Natl. Acad. Sci. U.S.A. 2013, 110, 18127). Here we present additional crystal structures, binding analyses, and bacterial killing studies of inhibitors that target both the active and pterin sites of a bNOS and function as antimicrobials. Together, these data provide a framework for continued development of bNOS inhibitors, as each molecule represents an excellent chemical scaffold for the design of isoform selective bNOS inhibitors.
UR - http://www.scopus.com/inward/record.url?scp=84921486202&partnerID=8YFLogxK
U2 - 10.1021/jm501723p
DO - 10.1021/jm501723p
M3 - Article
C2 - 25522110
AN - SCOPUS:84921486202
SN - 0022-2623
VL - 58
SP - 994
EP - 1004
JO - Journal of Medicinal Chemistry
JF - Journal of Medicinal Chemistry
IS - 2
ER -